| Mammaprint |
Van’t Veeret al.
[14]
|
2002 |
70 |
78 patients with sporadic primary breast tumors:<5 cm, N0, age <55 years; 34 patients developeddistant metastasis <5 years vs. 44 patients:disease-free >5 years |
Prognosis for distantmetastasis |
| Oncotype DX |
Paik et al.
[15]
|
2004 |
21 |
668 tumors from patients: N0 and ER+,treated with tamoxifen |
Prognosis for distantrecurrence/overall survival |
| MapQuant |
Sotirou et al.
[16]
|
2006 |
97 |
64 samples: ER+, grade 1 vs. grade 3 |
Prognosis for recurrence/relapse-free survival |
| Gene Search |
Wang et al.[17]
|
2005 |
76 |
115 tumors: all N0; 80 samples ER+,35 ER-, analyzed separately fordistant tumor recurrence,then combined |
Prognosis for distanttumor recurrence |
| Wound responsesignature |
Chang et al.
[18]
|
2004 |
512 |
50 fibroblast culturesfrom 10anatomic sites: response offibroblast to serum exposure |
Prognosis formetastasis/survival |
| Lung metastasissignature |
Minn et al.
[19]
|
2005 |
54 |
Comparison of highly and weaklylung-metastatic cell populationsderived from the breast cancercell line MDA-MB-231 |
Prognosis for lungmetastasis |
| Brain metastasissignature |
Bos et al.
[20]
|
2009 |
243 |
Comparison of cell lines withdifferent metastatic potentialsderived from the breast cancercell lines MDA-MB-231 and CN34 |
Prognosis for brainmetastasis |
| Bone metastasissignature |
Kang et al.
[21]
|
2003 |
102 |
MDA-MB-231 breast cancer cell line+12 derivative subpopulations withdifferent metastatic potentials |
Prognosis for bonemetastasis |
| Invasivenesssignature |
Liu et al.
[22]
|
2007 |
186 |
CD44+CD24−/low breast cancer cellswith high tumorgenic capacity vs. cellsof normal breast epithelium |
Prognosis for overall/metastasis-free survival |
| General metastasissignature |
Ramaswamyet al.
[23]
|
2003 |
128 |
64 primary adenocarcinomas of diverseorigin (lung, breast, prostate,colorectal, uterus, ovary) vs. 12unmatched adenocarcinoma metastasis |
Metastatic potential,clinical outcome |
| Meta genesignature |
Györffyet al.
[24]
|
2009 |
376 |
Meta-analysis of 20 published genesignatures on 7 breast cancermicroarray data sets (n = 1079) |
Prognosis forrelapse-free survival |
| 374 GeneSet/consensus genes |
Lausset al.
[25]
|
2008 |
374 |
Meta-analysis of 44 published genesignatures on 8 breastcancer microarray datasets (n = 1067) |
Prognosis forsurvival |
